

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	42	"5399700"	US-PGPUB; USPAT	OR	ON	2006/12/14 12:24
L2	29545	benzimidazole \$6prazole	US-PGPUB; USPAT	OR	ON	2006/12/14 12:25
L3	20444	cyclodextrin	US-PGPUB; USPAT	OR	ON	2006/12/14 12:25
L4	42	1 and (2 3)	US-PGPUB; USPAT	OR	ON	2006/12/14 12:42
L5	90	2 same 3	US-PGPUB; USPAT	OR	ON	2006/12/14 12:42
L6	66	5 not 1	US-PGPUB; USPAT	OR	ON	2006/12/14 12:42
L7	735	pantoprazole	US-PGPUB; USPAT	OR	ON	2006/12/14 12:42
L8	17	6 and 7	US-PGPUB; USPAT	OR	ON	2006/12/14 12:42

(FILE 'HOME' ENTERED AT 11:26:42 ON 14 DEC 2006)

FILE 'CAPLUS' ENTERED AT 11:26:57 ON 14 DEC 2006
S PANTOPRAZOLE/CN

L1 FILE 'REGISTRY' ENTERED AT 11:27:05 ON 14 DEC 2006
1 S PANTOPRAZOLE/CN

L2 FILE 'CAPLUS' ENTERED AT 11:27:05 ON 14 DEC 2006
807 S L1

L3 FILE 'REGISTRY' ENTERED AT 11:29:39 ON 14 DEC 2006
1 S L1

FILE 'CAPLUS' ENTERED AT 11:48:57 ON 14 DEC 2006
L4 929 S PANTOPRAZOLE
L5 9 S PROTONIX
L6 0 S ASTROPAN
L7 1 S PANTOR
L8 3 S PANTOLOC
L9 843 S PROTIUM
L10 7 S PANTOZOL
L11 0 S SCK 96022
L12 4 S SKF 96022
L13 5477 S BY 1023
L14 7282 S L2 OR L4 OR L5 OR L7 OR L8 OR L9 OR L10 OR L11 OR L12 OR L13
L15 32981 S CYCLODEXTRIN
L16 19 S L14 AND L15
L17 25044 S BENZIMIDAZOLE
L18 2568 S PROTON PUMP INHIBITOR
L19 4120 S PPI
L20 185 S L17 AND (L18 OR L19)
L21 2 S L20 AND L15
L22 0 S L21 NOT L16

L16 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:662596 CAPLUS
 DOCUMENT NUMBER: 145:217895
 TITLE: Pharmaceutical composition containing gastric parietal cell proton pump inhibitors and β -cyclodextrin derivative
 INVENTOR(S): Yin, Xiaofeng
 PATENT ASSIGNEE(S): Peop. Rep. China
 SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 17 pp.
 CODEN: CNXXEV
 DOCUMENT TYPE: Patent
 LANGUAGE: Chinese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1689568	A	20051102	CN 2004-10022415	20040429
PRIORITY APPLN. INFO.:			CN 2004-10022415	20040429

AB The title pharmaceutical composition contains gastric proton pump inhibitor or salts thereof or crystalline hydrate of the salts, and cyclodextrin derivative at a weight ratio of 1:(5-250), wherein the proton pump inhibitor refers to benzimidazoles, such as Omeprazole, Lansoprazole, Pantoprazole, their salts or crystalline hydrate of the salts; the cyclodextrin derivative may be hydroxypropyl- β -cyclodextrin or β -cyclodextrin sulfobutylether sodium salt. The composition may also contain other water-soluble adjuvant materials. The composition is suitable for parenteral administration, preferably i.v. drip and i.v. push injection, and has the advantages of improved stability and water solubility

L16 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:110042 CAPLUS
 DOCUMENT NUMBER: 144:280770
 TITLE: Novel voltammetric method for enantioseparation of racemic methotrexate
 AUTHOR(S): El-Hady, Deia Abd; Seliem, Mohamed Mahmoud; Gotti, Roberto; El-Maali, Nagwa Abo
 CORPORATE SOURCE: Department of Chemistry, Faculty of Science, Assiut University, Assiut, 71516, Egypt
 SOURCE: Sensors and Actuators, B: Chemical (2006), B113(2), 978-988
 CODEN: SABCEB; ISSN: 0925-4005
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB A carbon paste electrode is modified by hydrophobic mols. of hydroxypropyl α -cyclodextrin to form enantioselective membrane sensor. In neutral aqueous media, methotrexate (Mtx) enantiomers have been selectively accumulated at this enantioselective sensor depending on their hydrophilic/hydrophobic balance and then they can be quantified by voltammetric oxidation. The effect of solution and instrumental parameters on rac-Mtx enantioresoln. is investigated by using window diagram approach. The optimal exptl. conditions for these compds. were as follows: benproperine, mobile phase: 0.05 mol/L $\text{NH}_4\text{H}_2\text{PO}_4$ (pH 3.0)-acetonitrile (95:5, V/V), flow rate: 0.7 mL/min; MT-A5 and MT-Acid, mobile phase: 0.051 mol/L ammonium acetate (pH 5.0)-acetonitrile (74:26, V/V), flow rate: 0.7 mL/min; pantoprazole, mobile phase: 0.01 mol/L ammonium acetate (pH 5.5)-acetonitrile (93:7, V/V), flow rate: 0.9 mL/min; omeprazole and rabeprazole, mobile phase: 0.01 mol/L ammonium acetate (pH 3.0)-acetonitrile (95:5, V/V), flow rate: 0.7 mL/min; all the temps. were set at 20°C. The obtained resolution is sufficient to evaluate diastomer-Mtx at 0.1% (m/m of e-Mtx, the main compound). Selectivity of the proposed procedure is estimated by testing recovery and adding the most interfering metal ions and/or organic compds. The enantioselective sensor is satisfactorily used to investigate simultaneously ssDNA interactions with L-Mtx and D-Mtx. It is observed that the stability of D-Mtx-ssDNA diastereomeric complexation is higher than that of L-Mtx-ssDNA. These results are crucial in medical chemical for investigating many phenomena concerned with the carcinogenic effect of methotrexate. Using the com. available certified reference materials of L-Mtx and D-Mtx, the proposed enantioselective approach is validated to determine Mtx enantiopurity in its

tablets and injections with recovery values falling within the labeled amount of 90-110% with R.S.D. less than 6.00% required by US Pharmacopeia. Furthermore, high accuracy for application of the method to formulations is achieved and statistically confirmed by calculating F-test and t-test values at 95% confidence level.

REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 3 OF 19. CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1240817 CAPLUS

DOCUMENT NUMBER: 143:483155

TITLE: Stable pharmaceutical compositions containing benzimidazole derivatives and method of manufacturing the same

INVENTOR(S): Kim, Nam Ho; Choi, Jin Young; Kim, Jae Sun; Lee, Nam Kyu; Ryu, Je Ho; Hwang, Yong Youn; Oh, Yong Ho; Min, Dong Sun; Um, Key An; Kwak, Wie-Jong; Kum, Do Seung

PATENT ASSIGNEE(S): Sk Chemicals, Co. Ltd., S. Korea

SOURCE: PCT Int. Appl., 19 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005110488	A1	20051124	WO 2005-KR1214	20050427
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG KR 2005105565 A 20051104 KR 2004-30583 20040430 PRIORITY APPLN. INFO.: KR 2004-30583 A 20040430				

AB The present invention relates to an inclusion complex containing a benzimidazole derivative with excellent storage stability and a method of its preparation. In particular, the present invention relates to an inclusion complex containing a benzimidazole derivative with improved storage stability and a method of its preparation, where an inclusion complex is manufactured by performing an inclusion reaction by combining a benzimidazole derivative, cyclodextrin and a water-soluble polymer in an aqueous alkali solution in order to be formulated after stabilizing an acid-unstable benzimidazole derivative. For example, to a mixture of lansoprazole (369 mg, 1 mmol) and β - cyclodextrin (2.56 g, 2.2 15 mmol) was added hydroxypropyl Me cellulose in the amount of 20, 50, 100, 150 and 200 mg, resp., followed by 30 mL water and 1.2 mL of 1M-NaOH and then stirred at 50° for 6 h. Then, 74 mg of boric acid dissolved in 2.22 mL of distilled water was added thereto and stirred at 50° for 10 min. The reaction mixture was cooled down to 5° and kept in that condition for 18 h to form an inclusion complex. The inclusion complex was then filtered, washed several times with cold water and then dried under vacuum at 40° for 12 h to finally obtain a white inclusion complex, resp. The inclusion complexes obtained were shown to have superior storage stability as compared with the inclusion complexes and lansoprazole obtained in comparative examples.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1155541 CAPLUS

DOCUMENT NUMBER: 143:416253

TITLE: Combination of proton pump inhibitor, buffering agent, and prokinetic agent for treatment of gastric diseases

INVENTOR(S): Proehl, Gerald T.; Hall, Warren; Olmstead, Kay;

Hepburn, Bonnie

PATENT ASSIGNEE(S): Santarus, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 34 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005239845	A1	20051027	US 2005-107349	20050415
AU 2005249367	A1	20051215	AU 2005-249367	20050415
CA 2561700	AA	20051215	CA 2005-2561700	20050415
WO 2005117870	A2	20051215	WO 2005-US12863	20050415
WO 2005117870	A3	20060427		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-562820P P 20040416
 WO 2005-US12863 W 20050415

AB Pharmaceutical compns. comprising a proton pump inhibitor, one or more buffering agent and a prokinetic agent are described. Methods are described for treating gastric acid related disorders, using pharmaceutical compns. comprising a proton pump inhibitor, a buffering agent, and a prokinetic agent.

L16 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:902714 CAPLUS

DOCUMENT NUMBER: 143:235463

TITLE: Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent

INVENTOR(S): Proehl, Gerald T.; Olmstead, Kay; Hall, Warren

PATENT ASSIGNEE(S): Santarus, Inc., USA

SOURCE: PCT Int. Appl., 99 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005076987	A2	20050825	WO 2005-US3791	20050204
WO 2005076987	A3	20060608		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2005213472	A1	20050825	AU 2005-213472	20050204
CA 2554271	AA	20050825	CA 2005-2554271	20050204
US 2005249806	A1	20051110	US 2005-51260	20050204
EP 1718303	A2	20061108	EP 2005-722791	20050204

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU

PRIORITY APPLN. INFO.: US 2004-543636P P 20040210
 WO 2005-US3791 W 20050204

AB Pharmaceutical compns. comprising a proton pump inhibitor, one or more

buffering agent and a nonsteroidal anti-inflammatory drug are described. Methods are described for treating gastric acid-related disorders and treating inflammatory disorders, using pharmaceutical compns. comprising a proton pump inhibitor, a buffering agent, and a nonsteroidal anti-inflammatory drug. For example, a powder for suspension formulation contained omeprazole 20 mg, ibuprofen 400 mg, sodium bicarbonate 1895 mg, Xylitol 300 (sweetener) 2000 mg, sucrose (sweetener) 1750 mg, sucralose (sweetener) 125 mg, xanthan gum 17 mg, peach flavor 47 mg, and peppermint 26 mg.

LI6 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:638706 CAPLUS
 DOCUMENT NUMBER: 143:159548
 TITLE: Donepezil formulations
 INVENTOR(S): Boehm, Garth; Dundon, Josephine
 PATENT ASSIGNEE(S): Alpharma, Inc., USA
 SOURCE: PCT Int. Appl., 99 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005065645	A2	20050721	WO 2004-US42999	20041223
WO 2005065645	A3	20051027		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2552221	AA	20050721	CA 2004-2552221	20041223
US 2005232990	A1	20051020	US 2004-22346	20041223
PRIORITY APPLN. INFO.:			US 2003-533496P	P 20031231
			WO 2004-US42999	W 20041223

AB Donepezil formulations, including amorphous donepezil or pharmaceutically acceptable salts thereof; sustained-release formulations; and donepezil sprinkle formulations are disclosed.

LI6 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:423720 CAPLUS
 DOCUMENT NUMBER: 142:469276
 TITLE: Combination of proton pump inhibitor and sleep aid
 INVENTOR(S): Hall, Warren; Olmstead, Kay; Proehl, Gerald T.
 PATENT ASSIGNEE(S): Santarus, Inc., USA
 SOURCE: PCT Int. Appl., 73 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005044199	A2	20050519	WO 2004-US36989	20041105
WO 2005044199	A3	20050915		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,				

NE, SN, TD, TG

AU 2004287485	A1	20050519	AU 2004-287485	20041105
CA 2543164	AA	20050519	CA 2004-2543164	20041105
US 2005244517	A1	20051103	US 2004-982369	20041105
EP 1686976	A2	20060809	EP 2004-818347	20041105

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS

PRIORITY APPLN. INFO.: US 2003-517743P P 20031105
WO 2004-US36989 W 20041105

AB Pharmaceutical compns. comprising a proton pump inhibitor, one or more buffering agent and a sleep aid are described. Methods are described for treating gastric acid related disorders and inducing sleep, using pharmaceutical compns. comprising a proton pump inhibitor, a buffering agent, and a sleep aid. Capsules were prepared containing omeprazole, buffers, triazolam sleep aid and excipients.

L16 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:76250 CAPLUS

DOCUMENT NUMBER: 142:183426

TITLE: Pharmaceutical formulations useful for inhibiting acid secretion

INVENTOR(S): Hall, Warren; Olmstead, Kay; Weston, Laura

PATENT ASSIGNEE(S): Santarus, Inc., USA

SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005007115	A2	20050127	WO 2004-US22914	20040716
WO 2005007115	A3	20050428		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004257779	A1	20050127	AU 2004-257779	20040716
CA 2531564	AA	20050127	CA 2004-2531564	20040716
EP 1648416	A2	20060426	EP 2004-778425	20040716

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

PRIORITY APPLN. INFO.: US 2003-488321P P 20030718
WO 2004-US22914 W 20040716

AB In one general aspect of the present invention, oral pharmaceutical formulations comprising both a proton pump inhibitor microencapsulated with a material that enhances the shelf-life of the pharmaceutical composition and one or more antacid are described. In another general aspect of the present invention, pharmaceutical formulations comprising both a proton pump inhibitor microencapsulated with a taste-masking material and one or more antacid are described. For example, omeprazole was microencapsulated by spray drying of an aqueous mixture of Kollicoat IR, PEG 3350 and BHT at 10% of the encapsulated material. Encapsulated omeprazole (40 mg potency), sodium bicarbonate (1260 mg), calcium carbonate (790 mg), croscarmellose sodium (64 mg), Klucel (160 mg), Xylitab 100 (380 mg), microcryst. cellulose (128 mg), sucralose (162 mg), peppermint durarome (34 mg), peach flavor (100 mg), masking powder (60 mg), FD&C Lake Number 40 Red (3 mg), and magnesium stearate (32 mg) were pressed into chewable tablets with diams. of about 10 mm and average weight of approx. 600 mg per tablet.

L16 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:1038813 CAPLUS

DOCUMENT NUMBER: 142:397430

TITLE: Coacervation method and stability study of pantoprazole as an antiulcerative drug

AUTHOR(S): Nesseem, Demiana I.; Bebawy, Lories I.
CORPORATE SOURCE: National Organization for Drug Control & Research,
Cairo, Egypt
SOURCE: Bulletin of the Faculty of Pharmacy (Cairo University)
(2003), 41(2), 223-234
CODEN: BFPHAB; ISSN: 1110-0931
PUBLISHER: Cairo University, Faculty of Pharmacy
DOCUMENT TYPE: Journal
LANGUAGE: English

AB **Pantoprazole** is a derivative of benzimidazole, characterized by photochem. instability with the goal to improve its photostability. Microencapsulations were prepared with different varying weight ratios of different copolymers using polyacrylate-polymethyl acrylate copolymer (Eudragit E) or β **cyclodextrin** (β -CD) as enteric coating material and a simple coacervation method as coating process. USP XXIV dissoln. method was adopted and each formulation was simultaneously monitored for a period of 30 min and analyzed by HPLC. The percent of labeled dose dissolved was calculated at each time point for each formula from the corresponding regression equation. Evaluation of the suggested formulas were performed through, differential scanning calorimeter, and FTIR. In addition NMR was conducted to predict the possible drug-copolymer interaction or the complex formation. Furthermore stability indicating HPLC method for the quant. determination of **pantoprazole** in presence of its photodegrdn. has been described. HPLC assay in the method isocratic elution was used without prior extraction procedure for the drug.

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:757020 CAPLUS
DOCUMENT NUMBER: 139:281229
TITLE: Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
INVENTOR(S): Patel, Mahesh V.; Chen, Feng-Jing
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 51 pp., Cont.-in-part of U.S. Ser. No. 800,593.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 13
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003180352	A1	20030925	US 2002-159601	20020530
US 6248363	B1	20010619	US 1999-447690	19991123
US 2003064097	A1	20030403	US 2001-800593	20010306
US 6569463	B2	20030527		

PRIORITY APPLN. INFO.: US 1999-447690 A3 19991123
US 2001-800593 A2 20010306

AB The present invention provides solid pharmaceutical compns. for improved delivery of a wide variety of active ingredients contained therein or sep. administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides, and solubilizers. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides, and solubilizers. For example, beads were prepared containing omeprazole 8.8%, PEG-150 monostearate 27.8%, PEG-40 monostearate 13.9%, Maisine 35-1 4.6%, magnesium carbonate 0.9%, and nonpareil seed (30/35 mesh) 44.1%. The beads were further coated with an enteric coating layer by spraying a Eudragit L100 solution

L16 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:610242 CAPLUS
DOCUMENT NUMBER: 139:154933
TITLE: Transmucosal delivery of proton pump inhibitors
INVENTOR(S): Widder, Ken; Hall, Warren; Olmstead, Kay
PATENT ASSIGNEE(S): Santarus, Inc., USA

SOURCE: PCT Int. Appl., 38 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003063840	A2	20030807	WO 2003-US2659	20030127
WO 2003063840	A3	20030904		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2472103	AA	20030807	CA 2003-2472103	20030127
US 2004006111	A1	20040108	US 2003-353143	20030127
EP 1469839	A2	20041027	EP 2003-705972	20030127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005521662	T2	20050721	JP 2003-563534	20030127
PRIORITY APPLN. INFO.:				
			US 2002-351909P	P 20020125
			US 2002-374761P	P 20020422
			WO 2003-US2659	W 20030127

AB The present invention relates to pharmaceutical compns. and methods for transmucosal delivery of proton pump inhibitors. In one embodiment, the pharmaceutical composition of the present invention comprises a core which comprises an antacid, and an outer layer surrounding the core. The outer layer contains a therapeutically effective amount of a proton pump inhibitor. In another embodiment, the pharmaceutical composition of the present invention comprises an outer layer which comprising a unidirectional film, and an inner layer which contains a therapeutically effective amount of a proton pump inhibitor. In yet another embodiment, the pharmaceutical composition of the present invention is a unidirectional tablet for delivery of a proton pump inhibitor across the oral mucosa. In this embodiment, the pharmaceutical composition contains an outer layer which contains a pharmaceutically acceptable water impermeable layer, and an inner layer which contains a therapeutically effective amount of a proton pump inhibitor. A tablet composition contained in the outer layer; Klucel EXP 10, dicalcium phosphate 10, MgCO₃-90S 20, FD&C Lake Red Number 0.1, and Compitol-888 1 mg/tablet; the inner layer comprised omeprazole 20, MgCO₃-90S 20, Klucel EXP 10, and Mg stearate 0.6 mg/tablet.

L16 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:570853 CAPLUS
 DOCUMENT NUMBER: 139:122787
 TITLE: Pantoprazole cyclodextrin
 inclusion complexes
 INVENTOR(S): Giordano, Ferdinando; Marzocchi, Lucia; Moyano, Jose Ramon; Rossi, Alessandra
 PATENT ASSIGNEE(S): Altana Pharma A.-G., Germany
 SOURCE: PCT Int. Appl., 16 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003059393	A1	20030724	WO 2003-EP242	20030113
W: AE, AL, AU, BA, BR, CA, CN, CO, CU, DZ, EC, GE, HR, ID, IL, IN, IS, JP, KR, LT, LV, MA, MK, MX, NO, NZ, PH, PL, RO, SG, TN, UA, US, VN, YU, ZA, ZW RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
CA 2472395	AA	20030724	CA 2003-2472395	20030113

AU 2003202557 A1 20030730 AU 2003-202557 20030113
 EP 1467770 A1 20041020 EP 2003-701506 20030113
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
 JP 2005514443 T2 20050519 JP 2003-559553 20030113
 US 2005171057 A1 20050804 US 2003-501295 20030113
 PRIORITY APPLN. INFO.: EP 2002-288 A 20020115
 EP 2002-6454 A 20020322
 WO 2003-EP242 W 20030113

AB An inclusion complex formed from pantoprazole, a ATPase inhibitor used in therapy of disorders originating from increased gastric acid secretion, and cyclodextrin is described. For example, phase solubility studies of pantoprazole inclusion complexes with β - cyclodextrin, hydroxypropyl β - cyclodextrin (HP β -CD), and sodium salt sulfobutyl ether β - cyclodextrin obtained by freeze drying showed that with all three cyclodextrins, a notable increase in the apparent solubility of pantoprazole in phosphate buffer solution was observed. Inclusion complexation was not achieved through kneading. Freeze-drying permitted the preparation of an amorphous solid phase with HP β -CD and pantoprazole sodium from their aqueous solution.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:383079 CAPLUS
 DOCUMENT NUMBER: 140:117160
 TITLE: Oral pharmaceutical formulations for proton pump inhibitor
 AUTHOR(S): Anon.
 CORPORATE SOURCE: UK
 SOURCE: Research Disclosure (2003), 468(April), P523 (No. 467144)
 CODEN: RSDSBB; ISSN: 0374-4353
 PUBLISHER: Kenneth Mason Publications Ltd.
 DOCUMENT TYPE: Journal; Patent
 LANGUAGE: English
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RD 467144		20030310		

PRIORITY APPLN. INFO.: RD 2003-467144 20030310

AB The chemical formula is presented of an acid-labile benzimidazole in oral pharmaceutical formulations for proton pump inhibition. Components of a compressed tablet core, an intermediate barrier layer, and an enteric coat of the formulation are described.

L16 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:173369 CAPLUS
 DOCUMENT NUMBER: 138:210327
 TITLE: Preparation of pharmaceuticals containing cyclodextrin-drug complexes
 INVENTOR(S): Loftsson, Thorsteinn; Masson, Mar
 PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.
 SOURCE: PCT Int. Appl., 23 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003017921	A2	20030306	WO 2002-SE1519	20020826
WO 2003017921	A3	20031113		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,

KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
 CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002326275 A1 20030310 AU 2002-326275 20020826
 EP 1423094 A2 20040602 EP 2002-760974 20020826
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
 JP 2005503454 T2 20050203 JP 2003-522444 20020826
 US 2004242538 A1 20041202 US 2004-488123 20040227
 PRIORITY APPLN. INFO.: SE 2001-2856 A 20010827
 WO 2002-SE1519 W 20020826

AB This invention relates to a new method to improve the complexation efficacy of a basic active substance and a cyclodextrin using an acidic volatile substance. The invention further relates to a method to prepare high-energy complexes of a basic active substance and a cyclodextrin that form super-saturated solns. when dissolved. Also, the present invention relates to a pharmaceutical formulation comprising the complex and the use of such a formulation in therapy. Tamoxifen- β - cyclodextrin complexes were prepared by using 5 equiv of HOAc and using 2% β -CyD solution. The solution was lyophilized, the complex was sieved and heated in an oven for several days.

L16 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:114013 CAPLUS
 DOCUMENT NUMBER: 136:172763
 TITLE: Method for preparing an oral formulation containing acid-sensitive drugs
 INVENTOR(S): Hsiao, Fang-Hsiung; Lin, Chien-Chu; Changchien, Ya-Ching
 PATENT ASSIGNEE(S): Standard Chem. & Pharm. Co., Ltd., Taiwan
 SOURCE: U.S., 12 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6346269	B1	20020212	US 2000-567083	20000508
			US 2000-567083	20000508

PRIORITY APPLN. INFO.:

AB A method for preparing an oral formulation containing acid-sensitive drugs includes at least the following step: spreading a solution or a suspension containing at least stabilizers, solvents and acid-sensitive drugs or its pharmaceutically acceptable salts onto a core made from one or more excipients, and then drying the core to make an active ingredient layer over the core. The acid-sensitive drugs are substituted benzimidazole gastric anti-secretory agents selected from omeprazole, lansoprazole and pantoprazole. The oral formulation is a pellet, a tablet, or a minitabulet made by a wet granulation method. For example, pellets were prepared containing (a) a core, (b) a layer with an active ingredient containing omeprazole, hydroxypropyl cellulose (HPC), PEG, dibasic sodium phosphate, tribasic sodium phosphate, talc and water, (c) a sub-coating layer containing HPC, PEG, talc and water, and (d) an enteric-coating layer containing hydroxypropyl Me cellulose acetate succinate, talc and water. Pellets were filled in gelatin capsules which showed the average dissoln. rate lower than 10%.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:525902 CAPLUS
 DOCUMENT NUMBER: 135:111990
 TITLE: Enteric coated pharmaceutical formulation
 INVENTOR(S): Woolfe, Austen John
 PATENT ASSIGNEE(S): Norton Healthcare Ltd., UK
 SOURCE: PCT Int. Appl., 17 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001051031	A2	20010719	WO 2001-GB72	20010110
WO 2001051031	A3	20011227		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1185250	A2	20020313	EP 2001-900496	20010110
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRIORITY APPLN. INFO.:			GB 2000-482	A 20000111
			WO 2001-GB72	W 20010110

AB A method of making an oral pharmaceutical dosage form of an aqueous soluble drug includes the steps of: forming a solution or suspension of the drug, a soluble polymer and a binding or gelling agent; contacting the solution or suspension with an acid precipitating medium allowing the polymer to precipitate to form particles containing the dissolved drug; drying the particles; wherein the gelling or binding agent influences or prevents migration of the drug towards the surface of the particles during drying. Hydroxypropyl Me cellulose phthalate macroparticles were prepared using PVP and emulsions were freeze dried. Diclofenac was used for drug loading.

L16 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:475425 CAPLUS

DOCUMENT NUMBER: 133:94537

TITLE: Pharmaceutical formulations containing inclusion amino acid salts compounds of benzimidazole derivatives with cyclodextrins

INVENTOR(S): Mendes Cerdeira, Ana Maria; De Sousa Goucha, Jorge Pedro Manuel

PATENT ASSIGNEE(S): Tecnimed-Sociedade Tecnico-Medicinal, S.A., Port.

SOURCE: Eur. Pat. Appl., 27 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1018340	A1	20000712	EP 1999-670003	19990106
EP 1018340	B1	20030910		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AT 249218	E	20030915	AT 1999-670003	19990106
PT 1018340	T	20031231	PT 1999-670003	19990106
ES 2149750	T3	20040601	ES 1999-670003	19990106
PRIORITY APPLN. INFO.:			EP 1999-670003	A 19990106

AB The present invention concerns new very stable inclusion compds. from a hydrosol. basic amino acid salt of a benzimidazole derivative, namely omeprazole, lansoprazole and pantoprazole, and one or more cyclodextrins, preferably β - cyclodextrin; the process of their preparation, and their use in the manufacture of a medicine for the prophylactic and therapeutic treatment of duodenal gastric ulcer, gastro esophageal reflux disease and Zollinger-Ellison-syndrome are also disclosed. To a solution of 7.4 g L-arginine in 200 mL of water was added 3.0 g omeprazole followed by addition of 2.68 g of β - cyclodextrin and stirred for 2 h. After the lyophilization, the resulting inclusion compound (1:5:2) was kept at 40° and 75% RH for 6 mo to show degradation products of 0.8%. A tablet contained the above inclusion compound 86.8, microcryst. cellulose 213.0, colloidal silica 3.0, and magnesium stearate 3.0 g.

L16 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:190898 CAPLUS

DOCUMENT NUMBER: 132:241943

TITLE: Quick release oral pharmaceutical compositions

INVENTOR(S): Bertelsen, Poul; Hansen, Nils Gjerlov; Ruckendorfer, Hermann; Itai, Shigeru
 PATENT ASSIGNEE(S): Nycomed Danmark A/S, Den.
 SOURCE: PCT Int. Appl., 88 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000015195	A1	20000323	WO 1999-DK480	19990910
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2343148	AA	20000323	CA 1999-2343148	19990910
CA 2343148	C	20051115		
AU 9955045	A1	20000403	AU 1999-55045	19990910
EP 1109534	A1	20010627	EP 1999-941418	19990910
EP 1109534	B1	20030212		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200100708	T2	20010723	TR 2001-200100708	19990910
JP 2002524492	T2	20020806	JP 2000-569779	19990910
AT 232382	E	20030215	AT 1999-941418	19990910
PT 1109534	T	20030630	PT 1999-941418	19990910
ES 2190241	T3	20030716	ES 1999-941418	19990910
US 6713089	B1	20040330	US 2001-786864	20010710
US 2005147668	A1	20050707	US 2004-758233	20040113
PRIORITY APPLN. INFO.:				
			DK 1998-1143	A 19980910
			WO 1999-DK480	W 19990910
			US 2001-786864	A1 20010710

AB The present invention relates to an oral modified release pharmaceutical composition for the administration of a therapeutically and/or prophylactically effective amount of a drug to obtain a relatively fast or quick onset of the therapeutic and/or prophylactic effect. The drugs contained in a modified release pharmaceutical composition are substances which have a very low solubility under acidic conditions, i.e. under conditions similar to those present in the stomach and/or drugs which have a pKa value below about 5.5 such as in a range of from about 4 to about 5. The composition is based on a powder comprising a prophylactically active substance and has such a particle size that: when the powder is subjected to a sieve anal., then at least about 90% of the particles passes through sieves 180 <mm and the powder is contacted with an aqueous medium to form a particulate composition, which has such a particle size that when the particulate composition is subjected to a sieve anal., then at least about 50% of the particles passes through sieve 180 <mm. Furthermore, the composition, when tested in accordance with the dissoln. method (I) defined employing 0.07N HCl as dissoln. medium, releases at least about 50% of the active substance within the first 20 min of the test. Tablets were manufactured from ibuprofen 80.0, NaHCO3 400.0, Avicel PH-101 960.0, anhydrous calcium hydrogen phosphate 1104.0, L-HPC 480.0, hydroxypropyl cellulose 160.0, water 1080.0, EtOH 360.0 and calcium stearate 5.0 g/kg.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1996:718345 CAPLUS

DOCUMENT NUMBER: 125:339078

TITLE: Pharmaceutical composition containing hydroxypropyl- β - cyclodextrin-profenolol complex

INVENTOR(S): Penkler, Lawrence John; Whittaker, Darryl Vanstone

PATENT ASSIGNEE(S): Farmarc Nederland Bv of Citco Trust International, Neth.; Dyer, Alison Margaret

SOURCE: PCT Int. Appl., 37 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9632135	A1	19961017	WO 1996-GB737	19960327
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
ZA 9602214	A	19961007	ZA 1996-2214	19960319
AU 9651550	A1	19961030	AU 1996-51550	19960327
PRIORITY APPLN. INFO.:				
			ZA 1995-2938	A 19950410
			WO 1996-GB737	W 19960327

AB A pharmaceutical composition for administration as an injection or as a retention enema contains an inclusion complex of propofol and 2-hydroxypropyl- β -cyclodextrin, with approx. a 1:2 mol/mol stoichiometry the composition including a co-solvent where necessary. The pharmaceutical composition is prepared by preparing a solution of 2-hydroxypropyl- β -cyclodextrin and then adding an amt. of propofol to provide the desired molar ratio, and if necessary, adding the pharmaceutically acceptable cosolvent. Thus, in an aseptic environment, 1000 mL water for injection was used for dissolving 1023 g 2-hydroxypropyl- β -cyclodextrin followed by the addition of 52.0 g propofol. The solution was filtered into presterilized glass ampuls and was shown to be stable for at least 2 wk.